JACC Vol. 63, No. 7, 2014 ACC/AHA/SCAI/AMA-PCPI/NCQA February 25, 2014:722 45 Appendix B. Continued Peer Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Bene t Expert Witness Eric Stecker Content Reviewerd ACC Clinical Quality Committee None None None  Biotroniky  Medtronicy  Boston Scienti cy None None James E. Tcheng Content Reviewerd ACC/AHA Task Force on Data Standards None None None  Philips Medical Systemsy None None Randal J. Thomas Organizational Reviewerd AACVPR None None None None None None Thomas T. Tsai Content Reviewerd ACC NCDR Science and Quality Oversight Committee None None None None None None Thad Waites Of cial Reviewerd ACC Board of Trustees None None None None None None Tracy Y. Wang Content Reviewerd ACC/AHA Task Force on Data Standards  AstraZeneca  Medco Health Solutions None None  Bristol-Myers Squibb  Canyon Pharmaceuticals  Daiichi Sankyo  Eli Lilly  Heartscape  Merck  Sano -Aventis  The Medicines Company  Gilead None None Michael J. Wolk Content Reviewerd ACC Appropriate Use Criteria Task Force None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. 